Results 1 to 10 of about 9,568 (117)
Molecular Therapy - Methods and Clinical Development, 2023 Uridine diphosphate glucuronosyltransferases (UGTs) are highly expressed in the liver and are involved in the metabolism of many drugs. In particular, UGT1A1 has a genetic polymorphism that causes decreased activity, leading to drug-induced ...
Hiroyuki Mizuguchi +2 more
exaly +3 more sources
Recent progress and challenges in screening and characterization of UGT1A1 inhibitors
Acta Pharmaceutica Sinica B, 2019 Uridine-diphosphate glucuronosyltransferase 1A1 (UGT1A1) is an important conjugative enzyme in mammals that is responsible for the conjugation and detoxification of both endogenous and xenobiotic compounds. Strong inhibition of UGT1A1 may trigger adverse
Ling Yang, Yang-Liu Xia, Guangbo Ge
exaly +3 more sources
UGT1A1 polymorphisms in cancer: impact on irinotecan treatment
Pharmacogenomics and Personalized Medicine, 2017 Masashi Takano1 Toru Sugiyama2 1Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Saitama, 2Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Iwate, Japan Abstract: Mutations in the UGT1A1 ...
Masashi Takano
exaly +2 more sources
Genetic Association of UGT1A1 Promoter Variants (c.-3279T>G and c.-3156G>A) with Neonatal Hyperbili-rubinemia in an Iranian Population [PDF]
Iranian Journal of Neonatology, 2021 Background: Several studies have reported that two promoter variants (c.-3279T>G and c.-3156G>A) in UDP-glucuronosyltransferase (UGT1A1) gene may contribute to neonatal hyperbilirubinemia.
Nasim Pouralizadeh +6 more
doaj +1 more source
Cells, 2022 HepG2 cells are an inexpensive hepatocyte model that can be used for repeated experiments, but HepG2 cells do not express major cytochrome P450s (CYPs) and UDP glucuronosyltransferase family 1 member A1 (UGT1A1).
Ryosuke Negoro +4 more
doaj +1 more source
Genetic variations underlying Gilbert syndrome and HBV infection outcomes: a cross-sectional study
Frontiers in Genetics, 2023 Background: Constant cellular damage causes a poor prognosis of hepatitis B virus (HBV) infection. Accumulating evidence indicates the cytoprotective properties of bilirubin.
Bilian Yao +6 more
doaj +1 more source
Characteristics and Clinical Implication of UGT1A1 Heterozygous Mutation in Tumor
Chinese Journal of Lung Cancer, 2022 Background: The literature recommends that reduced dosage of CPT-11 should be applied in patients with UGT1A1 homozygous mutations, but the impact of UGT1A1 heterozygous mutations on the adverse reactions of CPT-11 is still not fully clear.
Qian LI +14 more
doaj +1 more source
Open Medicine, 2022 Genetic variation in UDP-glucuronosyltransferase 1A1 gene (UGT1A1) is a lithogenic risk factor for gallstone formation. This study aimed to assess genotype and allele frequencies of common UGT1A1 variants in patients with gallstone and hepatitis B virus (
Zhuo Haiyan +6 more
doaj +1 more source
Pharmacogenomic tests of oncology drugs at Instituto Nacional de Câncer (INCA)
Brazilian Journal of Oncology, 2021 The implementation, current status and future perspectives of the pharmacogenetics/genomics (PGx) testing program developed at Instituto Nacional de Cancer (INCA) are presented. Initial selection of drug-gene pairs for PGx testing was based on clinically-
Guilherme Suarez-Kurtz
doaj +1 more source
Clinical and Translational Science, 2022 Effects of UGT1A1*6 and UGT1A1*28 genetic polymorphisms on irinotecan‐induced severe toxicities in Asian cancer patients are inconclusive. Also, ABCC2 c.3972C>T may affect toxicity of irinotecan.
Chalirmporn Atasilp +8 more
doaj +1 more source